A novel PROTAC targeting the ERG protein is being developed to address metastatic castration-resistant prostate cancer (mCRPC). ERG gene fusions, found in up to 50% of prostate cancer cases, drive tumor progression and resistance to standard treatments. This therapy aims to degrade the ERG protein, effectively suppressing a key driver of cancer growth.
Preclinical studies have shown significant antitumor activity and effective ERG protein reduction. Backed by expertise demonstrated with a successful β-catenin/TCF4 clinical trials, this PROTAC represents a promising new avenue for treating advanced prostate cancer, with clinical trials anticipated in the near future.
Note: β-catenin is important for prostate cancer but their current clinical trial is focused on colorectal cancers, while this new PROTAC will be focused only on mCRPC
Dual ARi in mCRPCa - Antonarakis = 'Combo of 2 AR-directed agents should not be utilized in clinical practice at this time', MedPage 7/20/23